Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM

Diabetes Care

Volumn 21, Issue 4, 1998, Pages 597-603

  Tatti, Patrizio ^a   Pahor, Marco ^b   Byington, Robert P ^c   Di Mauro, Patrizia ^a   Guarisco, Riccardo ^a   Strollo, Giovanna ^d   Strollo, Felice ^d  

^a Centro Diabetico Ospedale di Marino   (Italy)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d INRCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN;

ACUTE HEART INFARCTION; ADULT; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC ANGIOPATHY; DOSE RESPONSE; FEMALE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STROKE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, HDL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; FOSINOPRIL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 0031944128     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.4.597     Document Type: Article

References (35)

1. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276:1886-1892, 1996
2. Harano Y, Kageyama A, Hirosa J, Asakura Y, Yokota T, Ikebuchi M, Suzuki M, Omae T: Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel-blocker amlodipine in essential hypertension subjects. Metabolism 44:315-319, 1995
3. Zehetgruber M, Beckmann R, Gabriel H, Christ G, Binder BR, Huber K: The ACE-inhibitor lisinopril affects plasma insulin levels but not fibrinolytic parameters. Thromb Res 83:143-152, 1996
4. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH: Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 43:1108-1113, 1994
5. Letizia C, De Ciocchis A, Cerci S, Coassin S, Fisher H, Tarsitani P, Scavo D: Amlodipine in ambulatory hypertensive patients: humoral and haemodynamic effects. Int J Clin Pharmacol Res 13:151-159, 1993
6. Schlueter W, Keilani T, Batlle DC: Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril. Am J Cardiol 72:37H-40H, 1993
7. Keilani T, Schlueter W, Levin B, Batlle DC: Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. Ann Intern Med 118:246-254, 1993
8. Ferrier C, Ferrari p, Weidmann P, Keller U, Beretta Piccoli C, Riesen WF: Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients. Drugs 44 (Suppl, 1):74-84, 1992
9. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
10. Kasiske BL, Ma JZ, Kalil RSN, Louis TA: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 122:133-141, 1995
11. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Cox DR: Regression models and life tables. J Roy Statist Soc 34B:187-220, 1972
13. SPSS: SPSS Advanced Statistics Reference Guide, release 7.5. Chicago, SPSS, 1997
14. Friedman L, Furberg C, DeMets D: Fundamentals of Clinical Trials. 3rd ed. St. Louis, MO, Mosby Yearbook, 1996
15. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Emler PJ, Cutler JA, Flack JM, Schoenenberger JA, McDonald R, Lewis CE, Leibson PR, Treatment of Mild Hypertension Study Research Group: Treatment of Mild Hypertension Study: final results. JAMA 270:713-724, 1993
16. Fortini A, Cappelletti C, Cecchi L, Laureano R: Fosinopril in the treatment of hypertension: effects on 24h ambulatory blood pressure and on blood pressure response to exercise. J Hum Hypertens 8:469-474, 1994
17. Bainbridge AD, Herlihy O, Meredith, PA, Elliott HL: A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol 45:425-430, 1993
18. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshmanan R, Gottdiener J, Ramirez EA, Henderson WG, the Department of Veteran Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents in men. N Engl J Med 328:914-921, 1993
19. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, LaRosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM: Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 9:342-360, 1996
20. Furberg CD, Psaty BM, Meyer JV: Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 92:1326-1331, 1995
21. Psaty BM, Heckbert SR, Koepsell TD, Siskovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274:620-625, 1995
22. Pahor M, Guralnik, JM, Corti C, Foley DJ, Carbonin PU, Havlik RJ: Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 43:1191-1197, 1995.
23. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan J, Wallace RB, Havlik RJ: Calcium channel blockade and incidence of cancer in aged populations. Lancet 348:493-497, 1996
24. Pahor M, Guralnik JM, Furberg CD, Carbonin PU, Havlik RJ: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 347:1061-1065, 1996
25. Alderman MH, Cohen H, Roque R, Madhavan S: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 349:594-598, 1997
26. Pahor M, Kritchevsky SB, Zuccala G, Guralnik JM: Diabetes and risk of adverse events with calcium antagonists (Letter). Diabetes Care 21:193-194, 1998
27. Terland O, Gronberg M, Flatmark T: The effect of calcium channel blockers on the H(+)-ATPase and bioenergetics of catecholamine storage vesicles. Eur J Pharmacol 207:37-41, 1991
28. Turpeinen AK, Vanninen E, Kuikka JT, Uusitupa MI: Demonstration of regional sympathetic denervation of the heart in diabetes: comparison between patients with NIDDM and IDDM. Diabetes Care 19:1083-1090, 1996
29. Trovik TS, Jaeger R, Jorde R, Sager G: Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness, Br J Clin Pharmacol 38:427-432, 1994
30. Juhan Vague I, Alessi MC, Vague P: Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28:371-380, 1996
31. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95:995-1001, 1995
32. Hamdan AD, Quist WC, Gagne JB, Feener EP: Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 93: 1073-1078, 1996
33. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting- enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
34. Zuanetti G, Latini R: Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. J Diabet Complications 11:131-136, 1997
35. Byington RP, Craven T, Furberg CD, Pahor M: Isradipine, raised glycosylated hemoglobin, and risk of cardiovascular events, Lancet 350:1075-1076, 1997